Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 376 clinical trials
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objectives of this study are to assess the safety, tolerability and efficacy of CK-301 when administered intravenously …

metastasis
cancer
ocular melanoma
endometrial carcinoma
monoclonal antibodies
  • 1806 views
  • 26 Jan, 2021
  • 41 locations
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

The primary Phase 1 purpose of this study is to assess overall safety and tolerability and recommended Phase 2 dose (RP2D) of APL-101. The Phase 2 portion will assess efficacy of the dose determined in Phase 1 in individuals with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations …

measurable disease
solid tumour
lung carcinoma
cancer
solid tumors
  • 144 views
  • 29 Jan, 2021
  • 84 locations
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health

This research study will test the efficacy of interactive, web-based interventions that improve diet, physical activity and weight management changes among early stage survivors of breast, prostate, colorectal, endometrial, renal, and ovarian cancers. Overarching outcomes also include physical function and performance, muscle mass, quality of life, and health utilities.

hypertension
ductal carcinoma
cancer
ovarian cancer
chemotherapy regimen
  • 42 views
  • 26 Jan, 2021
  • 2 locations
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

The purpose of this study is to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers

  • 506 views
  • 24 Jan, 2021
  • 10 locations
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced solid tumors or lymphomas.

psychiatric illness
cancer
cell transplantation
lymphoma
chemotherapy regimen
  • 26 views
  • 01 Feb, 2021
  • 5 locations
GEN1029 (HexaBody -DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

The purpose of the trial is to evaluate the safety of GEN1029 (HexaBody-DR5/DR5) in a mixed population of patients with specified solid tumors

measurable disease
solid tumour
metastasis
cancer
renal function test
  • 212 views
  • 23 Jan, 2021
  • 4 locations
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

This is a Phase IIb, multicohort, open-label multicenter study of combination immunotherapies in patients who have previously received treatment with PD-1/PD-L1 immune checkpoint inhibitors. All patients in Cohorts 1-4 will receive the combination treatment of PD-1/PD-L1 checkpoint inhibitor plus N-803 for up to 17 cycles. Each cycle is six weeks …

metastasis
cancer
serum pregnancy test
programmed cell death 1 ligand 1
erbb2
  • 457 views
  • 27 Jan, 2021
  • 36 locations
Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors

Based on the overwhelming positive response to this survey and the large number of patients being treated with PD-1/PD-L1 therapy in the UPMC system, the investigators are proposing a trial that will randomize patients who have disease stability to stop treatment at 1 year or continue treatment until disease progression. …

measurable disease
solid tumour
pd-l1
cancer
durvalumab
  • 15 views
  • 28 Jan, 2021
  • 1 location
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

carcinoma (NSCLC), and MK-4830 in combination with pembrolizumab + lenvatinib in renal cell cancer; and to evaluate objective response rate (ORR) in participants with advanced solid tumors treated with MK

metastasis
solid tumor
carcinoma
pembrolizumab
adenocarcinoma
  • 86 views
  • 01 Mar, 2021
  • 24 locations
A Study of PDR001 in Combination With LCL161 Everolimus or Panobinostat

The purpose of this study is to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.

  • 370 views
  • 27 Jan, 2021
  • 33 locations